KDR and cancer: This involves signaling in ECs themselves, e.g., adherence junctions 62, VEGFR2 signaling 63 and angiogenesis 64, or within the parenchyma, e.g., insulin signaling in neurons 65, as well as in pathological conditions like cancer 66, 67.